Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Exegenesis was founded in Hangzhou in July of last year by Zhenhua Wu, the current CEO, who has previously worked on gene therapy treatments for the likes of Merck, GlaxoSmithKline, and NeuExcell Therapeutics....
Singapore’s Openspace Ventures has hired Jessica Huang Pouleur (pictured), formerly of Providence Equity Partners and latterly head of Asia M&A for The Walt Disney Company, as an executive director.
The Blackstone Group has made a partial exit from Indian packaging manufacturer Essel Propack (EPL) – which provides the tubes to 40% of the world’s toothpaste – generating proceeds of INR18.6 billion ($253.4 million).
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.